Last reviewed · How we verify
bezafibrate (drug)
Bezafibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), leading to increased lipolysis and decreased lipogenesis.
Bezafibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), leading to increased lipolysis and decreased lipogenesis. Used for Hyperlipidemia, Dyslipidemia, Atherosclerosis.
At a glance
| Generic name | bezafibrate (drug) |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Fibrate |
| Target | PPAR-alpha |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This activation results in increased breakdown of triglycerides in adipose tissue and decreased synthesis of triglycerides in the liver. Additionally, bezafibrate has been shown to have anti-inflammatory properties and improve endothelial function.
Approved indications
- Hyperlipidemia
- Dyslipidemia
- Atherosclerosis
Common side effects
- Gastrointestinal disturbances
- Musculoskeletal pain
- Liver function abnormalities
Key clinical trials
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC (PHASE2)
- To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate (PHASE3)
- BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study (PHASE2)
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC (PHASE2)
- Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy (PHASE3)
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (PHASE2)
- Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bezafibrate (drug) CI brief — competitive landscape report
- bezafibrate (drug) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI